In a panel discussion that begins Saturday at 3:15 p.m. PT in Ballroom 20A-C, Ellen Leschek, MD, and others will discuss teplizumab clinical trial results and the role of the CD3-directed monoclonal antibody in delaying the progression from stage 2 type 1 diabetes to stage 3. Watch a livestream or catch the recording on the virtual platform at ADA2023.org.
Coming up: The New Normal—Perspectives on Treatment and Trials as Immunotherapies Enter the Type 1 Diabetes Clinical Landscape
